ArticleExperimental and therapeutic medicine2019
Dexmedetomidine enhances hypoxia-induced cancer cell progression.
Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- The impact of using dexmedetomidine during surgery on the postoperative survival of cancer patients: a meta-analysis and systematic review of real-world studies.Frontiers in pharmacology · 2026Pooled it
- Effect of intraoperative dexmedetomidine on prognosis in patients with cancer undergoing surgical procedures: a systematic review and meta-analysis.British journal of anaesthesia · 2025Pooled it
- Application Effect of Dexmedetomidine and Dezocine in Patients Undergoing Lung Cancer Surgery under General Anesthesia and Analysis of Their Roles in Recovery Time and Cognitive Function.Computational and mathematical methods in medicine · 2022Trial
- An Exploratory Study of High-Concentration Trace Amine Effects and Adrenoceptor Expression Patterns in SH-SY5Y Cells and Neuroblastoma.International journal of molecular sciences · 2026Article
- Dexmedetomidine inhibits microglia activation, neuroinflammation, and glycolysis in postoperative cognitive dysfunction by promoting YTHDF2-mediated PKM2 mRNA degradation.Molecular and cellular biochemistry · 2026Article
- Impact of perioperative dexmedetomidine on recurrence and survival outcomes in oral cavity squamous cell carcinoma.BMJ health & care informatics · 2025Article
- Impact of intraoperative dexmedetomidine on clear cell renal cell carcinoma progression: a retrospective cohort study.British journal of anaesthesia · 2025Article
- Mechanism of dexmedetomidine in inhibiting proliferation, migration, and invasion of esophageal squamous cell carcinoma cell through coagulation factor II receptor.Discover oncology · 2025Article
- Association between intraoperative dexmedetomidine and survival outcomes after colorectal cancer surgery: a retrospective cohort study.Frontiers in oncology · 2025Article
- Dexmedetomidine Suppresses Mitochondrial Autophagy and Apoptosis While Promoting Proliferation in Breast Cancer Cells in vitro via PI3K/AKT Signaling.Breast cancer (Dove Medical Press) · 2025Article
- Anesthetic Approaches and Their Impact on Cancer Recurrence and Metastasis: A Comprehensive Review.Cancers · 2024Review
- The Role of Anesthetic Management in Lung Cancer Recurrence and Metastasis: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Dexmedetomidine promotes colorectal cancer progression via Piwil2 signaling.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Anesthesia and cancer recurrence: a narrative review.Anesthesia and pain medicine · 2024Review
- Trial watch: dexmedetomidine in cancer therapy.Oncoimmunology · 2024Review
- Review
- Association between intraoperative dexmedetomidine and all-cause mortality and recurrence after laparoscopic resection of colorectal cancer: Follow-up analysis of a previous randomized controlled trial.Frontiers in oncology · 2023Article
- Enhanced Recovery After Surgery (ERAS) in Surgical Oncology.Current oncology reports · 2022Review
- Dexmedetomidine reversed hypoxia/reoxygenation injury-induced oxidative stress and endoplasmic reticulum stress-dependent apoptosis of cardiomyocytes via SIRT1/CHOP signaling pathway.Molecular and cellular biochemistry · 2021Article
- Anesthesia and Cancer, Friend or Foe? A Narrative Review.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dexmedetomidine (DEX) is widely used in perioperative settings for analgesia and sedation; however, little is known about its effects on the hypoxia-induced progression of tumor cells. In the present study, the effects of DEX on hypoxia-induced growth and metastasis of lung cancer cells and colorectal cancer cells was examined. A549 cells and HCT116 cells were treated with normoxia, hypoxia, co-treatment of hypoxia and DEX, and atipamezole (an α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.